Neuromuscular blocking agents (NMBAs) such as rocuronium and vecuronium are commonly used during general anesthesia, and all patients who are administered an NMBA have the potential to experience unintended post-operative residual neuromuscular blockade (PRNB). Though updated clinical guidelines published in 2023 now strongly recommend quantitative/objective train-of-four (TOF) monitoring of neuromuscular blockade, clinical adoption has been low.
In the first episode of this CMEOCast podcast series, Dr. Faulk and Dr. Renew will help learners to translate data into clinical practice regarding the differences between clinical assessment, qualitative assessment, and quantitative TOF monitoring and their efficacy in detecting residual neuromuscular blockade.
Identify the effects of clinical assessment, qualitative assessment, and quantitative monitoring on residual neuromuscular blockade.
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Physicians, nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists specializing in anesthesiology or surgery
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Renew reports the following financial relationships:
Research Support: Merck & Co., Inc (Funds to Mayo Clinic)
Dr. Faulk reports no financial relationships to disclose.
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).